Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIDSVAX B/E in HIV-uninfected Adults With SLE
NCT03618056Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AIDSVAX B/E in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Neutralizing Antibody Response Rate at 6.5 months, Neutralizing Antibody Magnitude at 6.5 months and 5 more. Started Dec 2018; status: completed.
02
Drugs
AIDSVAX B/E
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03618056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618056.